Maternal RSV vaccination, antibody therapy urged in new WHO recommendations

The World Health Organization connected Tuesday recommended maternal vaccination and the usage of an antibody therapy to forestall respiratory synctial microorganism (RSV) successful infants.

The recommendations, to administer some the changeable and the antibody oregon either, travel aft the WHO’s strategical advisory radical connected immunization met past week.

For countries that determine to usage a maternal vaccine, WHO said it recommends a azygous changeable successful the 3rd trimester of pregnancy.

Drugmaker Pfizer’s changeable is approved successful the United States and Canada for usage successful women during the mediate of the 3rd trimester of gestation to support their babies.

Trending Now

Last year, the U.S. Food and Drug Administration approved Sanofi SASY.PA and AstraZeneca’s AZN.L antibody therapy, Beyfortus, to forestall RSV successful infants and toddlers.

The manufacturers received support for an further manufacturing line in September for the therapy, arsenic its proviso was limited.

WHO’s strategical advisory radical besides noted the concerns astir proviso arsenic good arsenic the precocious outgo of the antibody therapy, which it said could earnestly bounds planetary entree and equity for the treatment.

RSV typically causes cold-like symptoms, but is besides a starring origin of pneumonia successful toddlers and older adults.